ZVRA Q2 2023 Earnings — Zevra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ZVRAZevra Therapeutics, Inc.

$618M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+551.5% YoY

Gross Profit

$8M92.0% margin

Operating Income

-$6M-73.8% margin

Net Income

-$3M-30.4% margin

EPS (Diluted)

$-0.15

QoQ Revenue Growth

+166.7%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$106M

Total Liabilities

$37M

Stockholders' Equity

$68M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$1M	+551.5%
Gross Profit	$8M	$1M	+523.9%
Operating Income	-$6M	-$25M	+74.8%
Net Income	-$3M	-$24M	+89.3%